A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy

Stefano Luminari,1,2 Antonio Pinto,3 Benedetta Puccini,4 Alessandro D’Arpino,5 Emanuela Omodeo Salè,6 Marco Bellone,7,* Lorenzo Pradelli,7 Alice Sabinot7,* 1Hematology, Azienda USL IRCCS of Reggio Emilia, Reggio Emilia, Italy; 2CHIMOMO Department, University of Modena and Reggio Emilia, Mode...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Luminari S, Pinto A, Puccini B, D’Arpino A, Omodeo Salè E, Bellone M, Pradelli L, Sabinot A
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Dove Medical Press 2025-04-01
Ráidu:	ClinicoEconomics and Outcomes Research
Fáttát:	economic evaluation oncology social cost hospital cost
Liŋkkat:	https://www.dovepress.com/a-cost-effectiveness-analysis-of-mosunetuzumab-vs-tisagenlecleucel-for-peer-reviewed-fulltext-article-CEOR
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!